Certara Inc (CERT)

Nov 5, 2026

Certara reported a 4% year-over-year revenue increase in Q3 2026, reaching $94.9 million, primarily driven by 11% growth in software revenue. The company also saw a 6% increase in adjusted EBITDA to $30.2 million, attributed to operational efficiencies. Certara is focusing on integrating AI, expanding cloud capabilities, and targeting growth in biotech, mid-sized pharma, and the APAC region, while narrowing its full-year revenue growth guidance to 2-3%.

Oct 29, 2026

Argus has raised its target price for Certara Inc. (CERT) to $9.00. The company, which trades under the symbol CERT in the Healthcare sector, is currently priced at $11.02. Certara Inc. utilizes biosimulation software and technology to expedite drug discovery and development processes.

Oct 28, 2026

Certara (CERT) shares have rallied 73% despite modest revenue and profit growth forecasts, driven by expectations of a turnaround in software momentum and new leadership. The upcoming third-quarter report is crucial to demonstrate whether this story is moving from promise to proof, particularly concerning the performance of its services segment and improved margins. The market is looking for solid bookings growth in software and signs that the recent commercial restructuring in services is effectively converting its pipeline.